AstraZeneca (AZN) stock came under pressure on Sept. 29 after the pharma giant announced a massive $2 billion investment in Summit Therapeutics (SMMT). As investors responded to the disclosure, AZN was briefly seen trading below its 20-day and 50-day moving averages (MAs), indicating bears are attempting to regain control in the near term.
Versus the start of 2026, AstraZeneca shares are down nearly 10% at the time of writing.